2024
Disorders due to Substance Use: General Approaches
Kosten T, Domingo C. Disorders due to Substance Use: General Approaches. 2024, 2527-2542. DOI: 10.1007/978-3-030-51366-5_92.Peer-Reviewed Original ResearchSubstance use disordersDSM-5ICD-11Depressive symptomsSubstance use disorder criteriaBorderline personality disorderSubstance-induced conditionsGoal of abstinenceDrug withdrawal symptomsPersonality disorderDepressive disorderAgonist maintenanceWithdrawal symptomsAcute detoxificationLifetime substanceSUD diagnosisAbused drugsDevelopmental differencesUrine toxicologySubstance useAlcohol usePsychosocial rehabilitationDisordersDrug useSymptomsCognitive enhancing effect of rTMS combined with tDCS in patients with major depressive disorder: a double-blind, randomized, sham-controlled study
Li X, Liu J, Wei S, Yu C, Wang D, Li Y, Li J, Zhuang W, Luo R, Li Y, Liu Z, Su Y, Liu J, Xu Y, Fan J, Zhu G, Xu W, Tang Y, Yan H, Cho R, Kosten T, Zhou D, Zhang X. Cognitive enhancing effect of rTMS combined with tDCS in patients with major depressive disorder: a double-blind, randomized, sham-controlled study. BMC Medicine 2024, 22: 253. PMID: 38902735, PMCID: PMC11188255, DOI: 10.1186/s12916-024-03443-7.Peer-Reviewed Original ResearchConceptsRBANS total scoreRepetitive transcranial magnetic stimulationTranscranial direct current stimulationMDD patientsTotal scoreHDRS-24Transcranial direct current stimulation groupDepressive disorderImmediate memoryDepressive symptomsCognitive dysfunctionHamilton Depression Rating ScaleTreatment of cognitive dysfunctionDepressed response ratesDepression Rating ScaleCognitive enhancing effectsTreating cognitive dysfunctionImprove neurocognitive impairmentsActive rTMS groupDouble-blindSafety of repetitive transcranial magnetic stimulationTranscranial direct current stimulation treatmentMDD inpatientsRepeatable BatterySessions of treatmentEfficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.
Fava M, Stahl S, Pani L, De Martin S, Cutler A, Maletic V, Gorodetzky C, Vocci F, Sapienza F, Kosten T, Kröger C, Champasa P, O'Gorman C, Guidetti C, Alimonti A, Comai S, Mattarei A, Folli F, Bushnell D, Traversa S, Inturrisi C, Manfredi P, Pappagallo M. Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial. The Journal Of Clinical Psychiatry 2024, 85 PMID: 38917366, DOI: 10.4088/jcp.24m15265.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating ScaleIntent-to-treatIntent-to-treat analysisStandard antidepressantsDepressive disorderPost hoc analysisBaseline Montgomery-Asberg Depression Rating ScaleInadequate response to standard antidepressantsSevere depressionPost hoc analysis of patientsDepression Rating ScaleMajor depressive disorderAnalysis of patientsAdverse eventsMontgomery-AsbergConsistent with prior studiesPlacebo-controlled trialRating ScaleEfficacy measuresPer-protocolIntent-to-treat populationTreatment adherencePhase 3 randomized controlled trialsAdjunctive treatmentMDDCorrelates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder
Bigdeli T, Barr P, Rajeevan N, Graham D, Li Y, Meyers J, Gorman B, Peterson R, Sayward F, Radhakrishnan K, Natarajan S, Nielsen D, Wilkinson A, Malhotra A, Zhao H, Brophy M, Shi Y, O’Leary T, Gleason T, Przygodzki R, Pyarajan S, Muralidhar S, Gaziano J, Huang G, Concato J, Siever L, DeLisi L, Kimbrel N, Beckham J, Swann A, Kosten T, Fanous A, Aslan M, Harvey P. Correlates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder. Molecular Psychiatry 2024, 29: 2399-2407. PMID: 38491344, DOI: 10.1038/s41380-024-02472-1.Peer-Reviewed Original ResearchBipolar I disorderSuicidal behaviorElectronic health recordsPolygenic scoresVeterans Health AdministrationSelf-reported SBColumbia-Suicide Severity Rating ScaleBipolar I disorder patientsCorrelates of suicidal behaviorClasses of psychotropic medicationsSelf-injurious behaviorHealth recordsSeverity Rating ScaleDiagnosed mental illnessAssociated with clinical variablesElectronic health record codesEHR domainDepressive disorderC-SSRSLifetime diagnosisSubstance-relatedPsychotropic medicationsSuicidal ideationExternalizing behaviorsSuicide attempts
2023
Disorders Due to Substance Use: General Approaches
Kosten T, Domingo C. Disorders Due to Substance Use: General Approaches. 2023, 1-16. DOI: 10.1007/978-3-030-42825-9_92-1.Peer-Reviewed Original ResearchSubstance use disordersDSM-5ICD-11Depressive symptomsSubstance use disorder criteriaBorderline personality disorderSubstance-induced conditionsGoal of abstinenceDrug withdrawal symptomsPersonality disorderDepressive disorderAgonist maintenanceWithdrawal symptomsAcute detoxificationLifetime substanceSUD diagnosisAbused drugsDevelopmental differencesUrine toxicologySubstance useAlcohol usePsychosocial rehabilitationDisordersDrug useSymptomsNo indication of abuse potential and absence of withdrawal from esmethadone in patients with major depressive disorder
Shram M, Pappagallo M, Henningfield J, Gorodetzky C, De Martin S, Vocci F, Sapienza F, Kosten T, Bushnell D, Guidetti C, O'Gorman C, Folli F, Traversa S, Inturrisi C, Manfredi P. No indication of abuse potential and absence of withdrawal from esmethadone in patients with major depressive disorder. Neuroscience Applied 2023, 2: 102965. DOI: 10.1016/j.nsa.2023.102965.Peer-Reviewed Original Research